Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase II drugs for Burkitt Lymphoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Subasumstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TAK-981 is under development for the treatment of advanced or metastatic solid tumors including microsatellite stable-colorectal cancer, cervical cancer, non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, small-cell lung cancer, head and neck cancer squamous cell carcinoma, melanoma, head and neck cancer and relapsed or refractory follicular lymphoma, small lymphocytic lymphoma, relapsed or refractory hematologic malignancy, chronic lymphocytic leukemia, lymphoplasmacytoid lymphoma, marginal zone lymphomas. The drug candidate is administered through intravenous infusion. It acts by targeting small ubiquitin-related modifier.
It was under development for mantle cell lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma, relapsed or refractory multiple myeloma.
Takeda Pharmaceutical overview
Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company, which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of drugs. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder; and its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.
For a complete picture of Subasumstat’s drug-specific PTSR and LoA scores, buy the report here.